Investor profile
Óskare Capital
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Headquartered in Paris and London, Óskare Capital specializes in venture-stage investments in the Deeptech and Life Sciences sectors. The firm advises Oskare Fund I ICAV (Dublin, Ireland), the first AIFMD-regulated and ESG-compatible venture capital fund focused on innovative European companies working on novel therapeutics — particularly cannabinoids and other molecules — that target the Endocannabinoid System (ECS), as well as the 'picks and shovels' of the associated ecosystem. The fund invests across the entire value chain from Seed to patient, but does not invest in cannabis production or recreational cannabis. As co-founder Alex Ouimet-Storrs notes: 'We have a hands-on approach; we not only inject capital but also provide business insight and introductions to potential investment partners and collaboration opportunities with industry experts and other startups in the ecosystem.'
Notable quotes
“Now that the sector is developing in Europe there is a need for a professional VC team to fuel, foster, and maximize the value creation. We have a hands-on approach; we not only inject capital but also provide business insight and introductions to potential investment partners and collaboration opportunities with industry experts and other startups in the ecosystem.”
“Based on my partnership with the ÓSKARE CAPITAL team over the last 9 months, I am convinced that Europe has the optimal regulatory and research environment to build the future key players in the global medical cannabinoid industry. The ÓSKARE CAPITAL team's strong scientific background and proven track record in pharma, venture capital and IP protection leverages proprietary deal flow and knowledge of the ecosystem to be successful.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Octarine Bio | Series A | $6m | 2026-01 |
| Octarine Bio | Pre-Seed | — | 2019 |
| Herbolea | Series A | $5m | 2021-10-26 |
| Leva | Seed | — | 2021 |
| Prohibition Partners | Series A | — | 2022 |
| Aelis Farma | Post-IPO | — | 2022 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| The Footprint Firm | 1 |
| Edaphon | 1 |
| Unconventional Ventures | 1 |
| dsm-firmenich Ventures | 1 |
| Houlihan Lokey (HNWI syndicate) | 1 |
Fit check
Is Óskare Capital a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit